Vaxcyte increases ATM equity offering capacity from $150M to $400M

Vaxcyte, Inc.

Amendment to Sales Agreement with Jefferies raises aggregate offering amount to $400M.
As of Feb 27, 2023, ~$137.8M had been sold under the prior $150M ATM program.
Material terms unchanged; sales made via at-the-market offerings on Nasdaq.
Shares registered under existing shelf registration statement; no obligation to sell.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.